Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Deals

Shineco Inc. Announces Acquisition of InfiniClone for Regenerative Medicine Expansion

Fineline Cube Apr 24, 2025

US-based Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Shineco Life Sciences Group Hong Kong...

Company Deals

Shenzhen Core Medical Closes Series D Round to Advance Miniaturized Artificial Hearts

Fineline Cube Apr 24, 2025

Shenzhen Core Medical Technology Co., Ltd, a developer of mechanical circulation assist systems, has reportedly...

Company Drug

Doer Biologics Begins Phase II Study of DR10624 for Steatotic Liver Disease

Fineline Cube Apr 24, 2025

China-based Zhejiang Doer Biologics Co., Ltd has announced the first patient dosing in a Phase...

Company Deals Drug

Boehringer Ingelheim Partners with Tessellate Bio on ALT Cancer Therapies

Fineline Cube Apr 24, 2025

Boehringer Ingelheim (BI), a German pharmaceutical leader, has entered into a strategic collaboration and global...

Company Deals

Genentech Collaborates with Repertoire Immune Medicines on Autoimmune Disease Therapies

Fineline Cube Apr 24, 2025

Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY) , announced a collaboration...

Company Deals

AstraZeneca Expands AI Partnership with Tempus AI and Pathos AI for Oncology Research

Fineline Cube Apr 24, 2025

UK pharmaceutical leader AstraZeneca (AZ, NASDAQ: AZN) has expanded its collaboration with US-based Tempus AI,...

Company

Boston Scientific Reports 20.9% Revenue Growth in Q1 2025 Financial Results

Fineline Cube Apr 24, 2025

US medical technology giant Boston Scientific Corporation (NYSE: BSX) released its Q1 2025 financial report,...

Company Medical Device

Roche Launches Navify Chest Pain Triage Algorithm With CE Mark

Fineline Cube Apr 24, 2025

Swiss healthcare giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it has received CE...

Policy / Regulatory

Trump Administration Considers Tying US Drug Prices to International Benchmarks

Fineline Cube Apr 24, 2025

Reuters reported that the Trump administration is exploring a policy to tie domestic drug prices...

Company Deals Drug

Baheal Partners with Jiluntai for Commercialization of Technetium-99m-labeled Imaging Agent

Fineline Cube Apr 24, 2025

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) has entered into a...

Company

PingAn Good Doctor Reports Q1 2025 Revenue Growth and Net Profit Turnaround

Fineline Cube Apr 24, 2025

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company Medical Device

MicroPort MedBot Gains NMPA Clearance for Toumai’s Remote Surgery Across Departments

Fineline Cube Apr 24, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced receiving clearance from China’s National...

Company Deals

QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb

Fineline Cube Apr 24, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has entered into a licensing agreement with...

Company

Roche Unveils $50 Billion Five-Year US Investment Plan to Expand Manufacturing and R&D

Fineline Cube Apr 23, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced a five-year investment plan totaling...

Company Deals

China Medical System Announces Spin-off of Dermavon for HKEX IPO

Fineline Cube Apr 23, 2025

China Medical System Holdings Limited (CMS; HKG: 0867) has announced the spin-off of its dermatology-focused...

Company Drug

BMS’s Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia

Fineline Cube Apr 23, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) has announced top-line results from the Phase III ARISE trial...

Company Drug

CSPC Gains NMPA Approval for Phase III Trial of Prusogliptin/Metformin FDC

Fineline Cube Apr 23, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured approval from the National Medical Products...

Company Drug

CSPC Pharmaceutical Gains FDA IND Clearance for JMT203 in Cancer Cachexia

Fineline Cube Apr 23, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) has obtained Investigational New Drug (IND) clearance from...

Company Drug

Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray

Fineline Cube Apr 23, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China’s National...

Company Drug

Biokin Receives NMPA Approval for CD33 ADC in AML Trial

Fineline Cube Apr 23, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...

Posts pagination

1 … 225 226 227 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.